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Abstract 
Complex formation between transcortin (corticosteroid-binding globulin) and 20 kDa sialoglycoprotein from human syncytiotro- 
phoblast plasma membranes (presumably a transcortin-recognizing subunit of the transcortin membrane r ceptor) was studied using FPLC 
and cross-linking with bifunctional reagents. The action of 1,5-difluoro-2,4-dinitrobenzene (DFDNB) on a solution of the purified 20 kDa 
sialoglycoprotein a d transcortin resulted in formation of covalently linked complexes of 95 kDa and 140 kDa consisting of one 
transcortin molecule and either two or four molecules of the membrane sialoglycoprotein (the molecular mass of transcortin is 55 kDa). 
Additionally, cross-linking resulted in the appearance of a 43 kDa species which is the cross-linked imer of the membrane protein. The 
dimer was also observed uring chromatography on a Superose 12 column in the absence of DFDNB treatment. Treatment of intact 
syncytiotrophoblast membranes with DFDNB resulted in isolation of the transcortin binding protein dimer as the major portion of total 
pool of the protein. Formation of the transcortin complexes with two and four molecules of the membrane protein was also observed 
when the membranes were incubated with 125I-labeled transcortin and treated with DFDNB, but formation of the latter complexes 
predominated. The results obtained suggest that the recognizing and binding domain for transcortin in placental membranes is organized 
as dimers consisting of non-covalently inked sialoglycoprotein monomers of a 20 kDa each and that transcortin has two sites for 
interaction with this dimer. Apparently, binding of two dimers results in the formation of the functional form of the transcortin-receptor 
complex. The possible biological role of such a complex is discussed. 
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1. Introduction 
Transcortin (or corticosteroid-binding globulin, CBG) - 
a glycoprotein of human and animal serum specifically 
binds corticosteroids and progesterone [1]. The main bio- 
logical function ascribed to this protein is to protect steroid 
hormones in the extracellular environment from destruc- 
tion and clearance and to deliver the hormones to target 
tissues. Studies of the last ten years provide evidence that 
transcortin is not only a passive extracellular t ansporter of 
steroids, but that it binds specifically to plasma membranes 
Abbreviations: DFDNB, 1,5-difluoro-2,4-dinitrobenzene; DMS, 
dimethyl suberimidate; FPLC, fast protein liquid chromatography; SDS- 
PAGE, sodium dodecylsulfate polyacrylamide gelelectrophoresis. 
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of cells in steroid hormone responsive tissues [2-9]. Fur- 
ther investigations revealed membrane-dependent degrada- 
tion of transcortin after interaction with plasma membrane 
of several rat tissues [6]. Internalization of transcortin by a 
mammary carcinoma [10] and human syncytiotrophoblast 
[11] cells and activation of the adenylate cyclase system 
[4,10] have also been shown to occur in these cells after 
interaction with transcortin. In all these experiments dis- 
tinct effects were observed only when steroid was bound 
to transcortin. These data suggest that transcortin is a 
prohormone which is activated by binding of steroid [10] 
and realizes any unknown functions at the membrane level 
or inside of the cell. 
Attempts to isolate membrane components responsible 
for transcortin binding revealed a 20 kDa sialoglycoprotein 
in plasma membranes of human decidual endometrium 
[12]. This protein is clearly different from asialoglycopro- 
tein receptor of liver [13] which participates in protein 
metabolism [14] and has been shown to bind asialo- 
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transcortin [15]. Further studies have shown that transcortin 
can form complexes with two or four molecules of the 
binding protein although the existence of this protein in the 
form of a dimer or tetramer has not been demonstrated 
[16]. It has been reported that two other membrane proteins 
are presumably involved with transcortin recognition [4], 
but no further evidence has been obtained that any protein 
except the 20 kDa sialoglycoprotein participates in 
transcortin recognition at the membrane surface. Recently 
we have shown the presence of a transcortin-binding pro- 
tein in plasma membranes from human syncytiotrophoblast 
[17,18], that is similar to that from decidual endometrium. 
Both of these proteins are sialoglycoproteins, have the 
same molecular mass, interact with transcortin with similar 
affinity and these interactions are steroid dependent. In the 
present report we studied the chromatographic behavior of 
the transcortin-binding protein and its transcortin complex 
and used cross-linking with bifunctional reagents to eluci- 
date the organization of the transcortin-binding site on 
syncytiotrophoblast plasma membranes. 
2. Materials and methods 
earlier described [21]. The preparation displayed a high 
activity of the plasmalemma marker enzyme 5'-nucleo- 
tidase (EC 3.1.3.5) [22] and had a normal vesicular struc- 
ture as was shown by electron microscopy. Labelling of 
the membranes was carried out using Iodo-Beads [23]. 
Membranes (about 10 mg membrane protein) were sus- 
pended in standard buffer (0.05 M Tris-HC1, pH 7.4, 0.15 
M NaC1) and incubated overnight with five Iodo-Beads 
and carrier-free Na125I (5 mCi) at 4°C with constant 
stirring. After that, Iodo-Beads were removed and the 
membranes were sedimented by centrifugation (25 000 × g, 
15 min). The membrane pellet was washed with the stan- 
dard buffer containing 0.15 M KI to replace non-reacted 
Na125I (three times with 50 ml buffer each) and with the 
standard buffer (three times with 50 ml buffer each) in 
order to remove non-reacted radionuclide. The labeled 
membrane pellet was suspended in the standard buffer 
(final volume of 2.5 ml) and solubilized by adding 2.5 ml 
of a 10% sodium cholate water solution and incubating 
this mixture for 3 h at 4 ° C with shaking. The mixture was 
then centrifuged (25 000 × g, 15 min), the supernatant was 
10-fold diluted with the standard buffer containing 5 - 10 -6 
M cortisol and was used for receptor isolation. 
2.1. Chemicals 2.4. Isolation of transcortin-binding protein 
Sepharose CL 4B, CNBr-activated Sepharose 4B and 
protein standards for electrophoresis and chromatography 
were purchased from Pharmacia (Uppsala, Sweden), 1,5- 
difluoro-2,4-dinitrobenzene (DFDNB), dimethyl suberimi- 
date (DMS), Iodo-Gen, and Iodo-Beads were purchased 
from Pierce (Rockford, IL, USA). Others chemicals were 
obtained from Serva (Heidelberg, Germany). 
2.2. Transcor~n 
Transcortin was isolated from human postpartum serum 
using affinity chromatography on cortisol-Sepharose [19]. 
Radiolabeled transcortin was prepared using NaleSI and 
Iodo-Gen as previously described [20]. Labeled transcortin 
was purified from the reaction mixture by chromatography 
on a Bio-Gel P-6 column (Bio-Rad, Richmond, CA, USA). 
Additional purification was performed on a Superose 12 
column using an FPLC system (Pharmacia). Specific activ- 
ity of the labeled protein preparations was approx. 50 
/zCi//zg and the radiochemical purity determined by pre- 
cipitation with trichloroacetic acid was 99%. More than 
95% of labeled transcortin in each preparation was bound 
by monospecific anti-transcortin a tibodies. Both, labeled 
and unlabeled transcortin preparations yielded one discrete 
band after native and SDS-electrophoresis. 
Transcortin-binding protein was isolated from syncy- 
tiotrophoblast plasma membranes by affinity chromatog- 
raphy on transcortin-Sepharose a  previously described 
[16]. The affinity resin was prepared by immobilization of 
transcortin on CNBr-activated Sepharose [24]. The 
transcortin content was 0.25 mg per ml settled gel volume 
as was determined by its capacity to bind cortisol. A 
column was packed with approx. 5 ml of the resin and was 
equilibrated with the standard buffer. The membrane solu- 
bilizate was applied to the column at a flow rate of 3 
ml/h. To remove non-specifically adsorbed radioactive 
material, the column was extensively washed with the 
standard buffer containing 1 mg/ml ovalbumin and 5. 
10 6 M cortisol until the radioactivity eluting from col- 
umn was decreased to about 50000 cpm per ml of eluate. 
Elution of the transcortin-binding protein was then per- 
formed using standard buffer containing 1 mg/ml 
transcortin and 5 • 10  -6  M cortisol. The elution rate was 2 
ml/h. In another experiment the elution was done using 
standard buffer containing 1 mg/ml ovalbumin and 1. 
10 -5 M testosterone [18]. The affinity eluate was desalted 
by filtration through Bio-Gel P-6, freeze-dried and stored 
at - 20 ° C for no longer than one week. 
2.5. FPLC 
2.3. Membrane preparation 
A microvesicular fraction was prepared from the syncy- 
tiotrophoblast brush border of human term placenta as 
A Superose 12 column and an FPLC system (Pharmacia, 
Uppsala, Sweden) were used. Samples (0.1 ml, about 
25 000-30 000 cpm of affinity eluate) were applied to the 
column in 0.05 M Tris-HC1 buffer (pH 7.4) with a flow 
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rate of 0.2 ml/min. Fractions of 0.4 ml were collected and 
radioactivity in the fractions was measured at 80% effi- 
ciency using an RIA Gamma counter (LKB-Wallac, Turku, 
Finland). 
and radioactivity in the slices was measured at an 80% 
efficiency using RIA Gamma counter (LKB-Wallac, Turku, 
Finland). 
2.6. Cross-linking experiments 3. Results 
Cross-linking of transcortin-binding protein with DMS 
was carried out essentially as described by Davies and 
Stark [25]. To cross-link the complex of transcortin and its 
binding protein with DFDNB, a solution of DFDNB in 
dimethyl sulfoxide was added to 0.2 ml of the affinity 
eluate (about 50000 cpm) in Krebs-Ringer bicarbonate 
buffer (pH 7.4) to a final concentration 0.25 mg/ml. The 
mixture was then incubated for 4 h at 4 ° C after which 
0.025 ml of 1.0 M Tris-HC1 buffer (pH 7.4) was added to 
the sample and the sample was incubated for 30 min at 
room temperature. The cross-linked sample was desalted 
by filtration through Bio-Gel P-6 column and was ana- 
lyzed by SDS-PAGE on a 5-8% gradient gel. 
To cross-link components of the transcortin-recognizing 
domain, syncytiotrophoblast plasma membranes (about 10 
mg membrane protein) were treated with DFDNB (0.2 and 
0.02 mg/ml final concentration) in Krebs-Ringer buffer 
overnight at 4 ° C with constant stirring. Excess of non-re- 
acted DFDNB was removed by washing with 50 ml of 
Krebs-Ringer buffer five times. After that, membranes 
were labeled, solubilized and applied to the immobilized 
transcortin column. After elution of the column with 
transcortin containing buffer, eluate was analyzed by 
SDS-PAGE in a 12.5% gel. 
To cross-link transcortin with syncytiotrophoblast 
plasma membranes, 12sI-transcortin (4/~Ci) was incubated 
with the membrane suspension (about 2 mg membrane 
protein) in 1 ml of Krebs-Ringer buffer containing 5 • 10 6 
M cortisol. For the control sample, a 500-fold molar 
excess of unlabeled transcortin was added to the mem- 
branes together with labeled transcortin. The samples were 
incubated overnight at 4 ° C with shaking; then the mem- 
branes were sedimented by centrifugation for 15 min at 
12000Xg and the supernatants were discarded. The 
membrane pellets were twice washed with the buffer and 
were resuspended in 0.2 ml of the buffer. DFDNB dis- 
solved in dimethyl sulfoxide was added to the samples up 
to a final concentration of 0.2 and 0.02 mg/ml. The 
samples were incubated 4 h at 4 ° C with constant stirring. 
The non-reacted substances were removed by washing the 
membranes with the buffer (three times) and with distilled 
water (three times). Treated membranes were suspended in
0.2 ml distilled water and were analyzed by SDS-PAGE on 
a 5% gel. 
2. 7. SDS polyacrylamide gel electrophoresis 
SDS-PAGE was performed according to Laemmli [26]. 
After electrophoresis each lane was cut into 0.25 cm slices 
3.1. Chromatographic mobility of transcortin-binding pro- 
tein 
Chromatography on Superose 12 was used to examine 
the hydrodynamic properties of the transcortin-binding 
protein and its transcortin complex with the aim of eluci- 
dating the stoichiometry of interaction between transcortin 
and its binding protein in their complex. The 125I-trans- 
cortin-binding protein elutes from Superose 12 as one 
major peak which coincides with protein of about 43-45 
kDa (Fig. 1A). A second peak was observed at the void 
volume of the column and corresponded to substances of 
about 2000 kDa; this peak disappeared when chromatog- 
raphy was carried out in the presence of 0.5% sodium 
cholate (data not shown). When chromatography was con- 
ducted in the presence of transcortin, a poorly resolved 
biphasic peak occurred between the void volume and the 
transcortin-binding protein peak (Fig. 1B). Using radioim- 
munoassay, we examined the chromatographic fractions 
for the presence of transcortin. The maximum transcortin 
concentration corresponded with the elution of the protein 
itself (fractions 31-32). Transcortin was also present in the 
radioactive peak corresponding to fractions 25-29. These 
results indicate that the radioactive peak in fractions 25-29 
is a complex (or complexes) of the membrane protein and 
transcortin. The mobilities of the complexes correspond to 
proteins with molecular masses of a 120-200 kDa. The 
heterogeneous profile of the peak corresponding to the 
complexes did not permit us to determine the stoichiom- 
etry of the interaction of transcortin with its binding 
protein. When the 125I-labeled transcortin binding protein 
was chromatographed in the presence of 6.0 M urea, the 
earlier observed 45 kDa peak disappeared and a protein 
with a molecular mass of about 20 kDa was detected (Fig. 
1C). However, high molecular weight aggregates were 
present at or near the void volume of the column (Fig. 
1A-C). 
3.2. Cross-linking of transcortin-binding protein and 
transcortin 
For cross-linking experiments we used DFDNB, which 
has been successfully applied for cross-linking of proteins 
in solution [27], and for cross-linking to membranes [28], 
and DMS which has been largely used to study non-cova- 
lent protein oligomer formation [29,30]. To study the 
stoichiometry of the complex between transcortin and its 
binding protein we cross-linked a mixture of lesI-labeled 
transcortin-binding protein and transcortin solution. Prior 
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to cross-linking, the 125I-transcortin-binding protein mi- 
grated on SDS-PAGE as a single band with a relative 
mobility corresponding to that of trypsin inhibitor (20.1 
kDa, Fig. 2A). Cross-linking with DFDNB resulted in the 
appearance of three additional bands corresponding to 
species with molecular masses of 43 kDa, 95 kDa and 140 
kDa (Fig. 2B). These bands correspond to transcortin-bind- 
ing protein cross-linked to itself (43 kDa) and transcortin 
cross-linked to one (95 kDa) and two (140 kDa) binding 
protein dimers. The molecular mass of transcortin is 55 
kDa [31]. After cross-linking with DMS, only one addi- 
tional band of 43 kDa appeared (data not shown) indicat- 
ing that this reagent is capable of cross-linking the binding 
protein to itself, but that is not able to cross-link transcortin 
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Fig. 2. SDS-PAGE of cross-linked 1251-labeled transcortin-binding pro- 
tein. The purified labeled protein was cross-linked in solution with 
DFDNB in the presence and in the absence of transcortin and the 
cross-linked species were analyzed by SDS-PAGE. The gel was cut into 
0.25 cm slices and radioactivity of the slices was measured. (A) Purified 
transcortin-binding protein without cross-linking. (B) The protein after 
cross-linking in the presence of transcortin. (C) The protein after cross- 
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ovalbumin, 43 kDa (4), carbonic anhydrase, 30 kDa (5), trypsin inhibitor, 
20.1 kDa (6). 
to the binding protein. Cross-linking of the binding protein 
itself (in the absence of transcortin) with DFDNB or DMS 
led to the appearance of one extra band corresponding to 
the 43 kDa binding protein dimer (Fig. 2C, shown data for 
DFDNB). 
3.3. Cross-linking of the transcortin-binding domain on the 
membrane surface 
To elucidate the organization of the transcortin-binding 
domain on syncytiotrophoblast membranes we cross-linked 
isolated membranes with DFDNB. After that, cross-linked 
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Fig. 3. SDS-PAGE of the transcortin-binding protein isolated from native 
and DFDNB treated membranes. (A) The protein from non-treated mem- 
branes. (B) The protein from membranes treated with 0.025 mg/ml 
DFDNB. (C) The protein from membranes treated with 0.25 mg/ml 
DFDNB. Arrows indicate position of standards: phosphorylase b (1), 
bovine serum albumin (2), ovalbumin (3), carbonic anhydrase (4), trypsin 
inhibitor (5). 
membranes were non-specifically labeled with 125I and 
components possessing affinity for transcortin were iso- 
lated by affinity chromatography on immobil ized 
transcortin and analyzed by SDS-PAGE. Analysis of mem- 
brane components before cross-linking indicated a single 
peak (Fig. 3A) having a relative molecular mass 20 kDa 
which represents the transcortin-binding protein monomer. 
Cross-linking results in the appearance of a transcortin-bi- 
nding component with a molecular mass of a 43 kDa 
(transcortin binding protein dimer, Fig. 3B) in addition to 
the 20 kDa transcortin-binding protein. Increasing the con- 
centration of DFDNB resulted in an increase in the amount 
of 43 kDa dimer species and a decrease in the amount of 
20 kDa species (Fig. 3C). These data indicate that 
transcortin-binding protein monomers can be cross-linked 
to each other while they are in their native position in the 
plasma membrane. 
3.4. Cross-linking of transcortin with its membrane bind- 
ing domain 
To study complex formation between transcortin and 
membrane component(s), we used DFDNB to cross-link 
125I-transcortin after its binding to the membranes. To 
estimate non-specific interaction of transcortin with the 
membranes, cross-linking was performed in the presence 
of an excess of unlabeled transcortin. Two concentrations 
of DFDNB were used in these experiments -0 .25  mg/ml  
and 0.025 mg/ml .  To insure complete dissociation of 
membrane proteins after cross-linking, the membranes were 
boiled with a 2% SDS/5% 2-mercaptoethanol s lution for 
30 min. SDS-PAGE analysis of the membrane preparation 
after cross-linking with labeled transcortin revealed two 
bands corresponding to protein species with molecular 
mass of 140 kDa and 95 kDa (Fig. 4A) in addition to the 
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Fig. 4. SDS-PAGE of syncytiotrophoblast plasma membranes after 
cross-linking with labeled transcortin. (A) Cross-linking with 0.025 
mg/ml DFDNB. (B) Cross-linking with 0.25 mg/ml DFDNB. (C) 
Cross-linking with 0.25 mg/ml DFDNB in the presence of an excess of 
unlabeled transcortin. Arrows indicate position of standards: covalently 
linked dimer of bovine serum albumin (1), phosphorylase b (2), bovine 
serum albumin (3), ovalbumin (4). 
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55 kDa 125I-transcortin that was bound to membranes 
non-covalently, and was not removed during the wash. 
These bands would correspond to transcortin cross-linked 
to four and two transcortin binding proteins, respectively. 
Increasing the concentration of DFDNB resulted in an 
increase in the 140 kDa species and a decrease in the 95 
kDa band (Fig. 4B). The band at the top of the gel was 
observed after cross-linking with labeled transcortin alone 
or in the presence of an excess of unlabeled transcortin 
(Fig. 4A-C), indicating the non-specific nature of the 
band. If cross-linking was performed in the presence of an 
excess of unlabeled transcortin (Fig. 4C), the 140 and 95 
kDa bands were eliminated indicating that there are a 
limited number of transcortin binding sites in the mem- 
brane preparation and suggesting a specific interaction of 
transcortin with membrane components. 
4. Discussion 
We have recently demonstrated [16] that the functional 
form of the 20 kDa transcortin-binding protein from en- 
dometrium plasma membranes, which presumably consti- 
tutes the recognizing subunits of the transcortin membrane 
receptor, is a tetramer. The transcortin-binding protein 
which we have isolated from syncytiotrophoblast mem- 
branes has similar properties and the data suggest hat it 
also has an oligomeric structure. 
Mobility of the 20 kDa transcortin-binding protein as a 
45 kDa species during gel-permeation chromatography 
under non-denaturing conditions indicates that the protein 
is organized as a dimer. Cross-linking experiments also 
indicate that dimerization of the protomers occurs. Homo 
or hetero dimers have been observed for several membrane 
receptors from different receptor families [32-36]. The 
constant of association of the protomers to form the 
transcortin-binding protein dimer is apparently very high 
since the whole pool of isolated protein is present as the 
dimer. Disulfide bond formation is not involved in dimer- 
ization since a single 20 kDa band is present following 
SDS-PAGE under both reducing and non-reducing condi- 
tions. The presence of urea which dissociates non-covalent 
protein complexes during gel-permeation chromatography 
[37,38], resulted in dissociation of the dimer into monomers 
thus confirming non-covalent nature of the dimer. In our 
experiments, formation of high molecular weight aggre- 
gates of the transcortin-binding protein has been observed. 
Although the tendency of membrane proteins to form 
aggregates is a commonly known non-specific process, the 
aggregation of receptors in the membrane bilayer can be 
the next step in receptor action after ligand binding [39]. 
This phenomenon is related to interactions between the 
aggregated protein and other cellular components [40]. We 
can not make definite conclusions about the nature of the 
aggregation in our case, but we do note, that in the 
presence of transcortin, higher states of aggregation oc- 
curred. 
Effective cross-linking with DFDNB indicates close 
contact between transcortin and its binding protein and 
between the monomers of the binding protein, since this 
reagent links reactive groups located at a distance of 3-5 
A [41]. The fact that transcortin forms complexes with two 
and four molecules of binding protein coincides with our 
observation for transcortin binding protein from decidual 
endometrium embranes [16]. An explanation for the ef- 
fectiveness of DFDNB and the ineffectiveness of DMS in 
cross-linking of the complexes of transcortin with its bind- 
ing protein may be that DMS is able to interact only with 
primary amines while DFDNB has a larger spectrum of 
reactions [27]. 
When cross-linking studies were performed on the 
transcortin-binding protein itself, formation of tetramers 
did not occur. However, cross-linking studies with DFDNB 
in the presence of the binding protein and transcortin 
indicated two or four molecules of the binding protein 
interacted with transcortin. These observations lead us to 
propose that transcortin binds to two dimers of the binding 
protein rather than to a tetramer and that the two dimers 
are not in close contact o each other on the surface of the 
transcortin molecule. At the same time, we cannot exclude 
the possibility that binding protein tetramers are present 
when the binding protein is incorporated into the structure 
of plasma membrane. However, cross-linking of mem- 
branes with DFDNB also resulted in the isolation of the 
transcortin-binding protein primarily in the form of dimers. 
This observation strengthens our supposition that 
transcortin-binding protein interacts with transcortin as a 
dimer. Monomers were also observed after membrane 
cross-linking, this is probably due to incomplete cross-lin- 
king since increasing the concentration f DFDNB resulted 
in an increase in the relative content of dimer in compari- 
son with monomer. Cross-linking of labeled transcortin 
with plasma membranes also provides evidence that only 
the dimer or two dimers, but not monomers, recognize and 
bind transcortin. Although on membranes transcortin can 
be bound to one dimer, the fact that the 140 kDa peak 
(Fig. 4A and B) greatly exceeds the 95 kDa peak indicates 
that binding to two dimers is preferable. This type of 
membrane receptor organization is known. For instance 
association of two dimers of insulin-like growth factor I 
receptor is required for the formation of a high-affinity 
binding site [42]. 
The above data suggest that the dimers are organized in 
clusters on the membrane surface. The existence of recep- 
tor clusters in the absence of ligand [39,43] or, at least the 
presence of adjacent receptor molecules has been observed 
[44]. Thus, if the dimer is the transcortin recognizing and 
binding unit, two dimers apparently represent the func- 
tional domain. We suggest hat binding of transcortin to 
the two dimers initiates further processes. The other 
transcortin-binding protein with similar properties i olated 
from plasma membranes of human endometrium [12] was 
also demonstrated to form a complex with transcortin in 
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which four molecules of the protein interact with one 
molecule of transcortin [16]. But in endometrium mem- 
branes the protein has been found to exist as a monomer 
[16], while in placental membranes the transcortin-binding 
protein is present as non-covalent dimers. It is possible that 
both transcortin-binding proteins are encoded by the same 
gene and differences between the proteins are a result of 
post-translation modification. Apparently, such a differ- 
ence is tissue-specific and results in formation of different 
transcortin-binding domains on membrane surface that may 
reflect differences in amount of transcortin-binding sites 
and/or  affinity constant for transcortin binding. It could 
provide an additional regulatory mechanism at the tissue 
level. At present we have no information concerning the 
possible biological role of the membrane transcortin-bind- 
ing proteins, but we suggest that the transcortin-binding 
domain is a system for transmembrane transfer of 
transcortin and/or  is part of a signal transduction system. 
A number of studies [45-48] showing the presence of 
transcortin-like protein in the cytoplasm of several tissues 
provides indirect evidence for transcortin internalization 
mechanisms. The fact that transcortin can be taken up by 
syncytiotrophoblast membrane vesicles [11] also supports 
this suggestion. The stimulation of adenylate cyclase by 
transcortin [4,10] provides evidence for a signal transduc- 
tion role of the transcortin-binding protein complex. Eluci- 
dation of the role of the complex of transcortin with the 
binding protein in the mechanism of transcortin action 
awaits future studies. 
5. Note added in proof (received 16 February 1995) 
It has been reported that, in placental membranes, there 
are two types of binding site for transcortin [9], which 
differ in affinity and binding capacity. As we have found 
only one type of transcortin-binding protein in these mem- 
branes, we suggest hat low- and high-affinity transcortin 
binding reflects binding with dimers or tetramers and, 
apparently, binding with the latter occurs with higher 
affinity. If this is the case, the binding capacity of low- and 
high-affinity sites may indicate the amount of dimer dis- 
persed on the membrane surface or organized in clusters. 
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